Alec Machiels - 17 Feb 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Alec Machiels
Issuer symbol
APLS
Transactions as of
17 Feb 2023
Net transactions value
-$62,138
Form type
4
Filing time
21 Feb 2023, 15:22:07 UTC
Previous filing
19 Jan 2023
Next filing
21 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $3,338 +1,250 +0.47% $2.67* 268,891 17 Feb 2023 Direct F1
transaction APLS Common Stock Sale $65,475 -1,250 -0.46% $52.38 267,641 17 Feb 2023 Direct F1
holding APLS Common Stock 250,000 17 Feb 2023 Indirect Owner (Bauhaus 1 LLC) F2
holding APLS Common Stock 11,950 17 Feb 2023 Indirect Owner (Owned by Spouse) F3
holding APLS Common Stock 150,000 17 Feb 2023 Indirect Owner (Spouse Trust) F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -1,250 -1.1% $0.000000 111,029 17 Feb 2023 Common Stock 1,250 $2.67 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is a scheduled exercise and sale from 10B5-1 trading plan.
F2 The shares are held by Bauhaus 1 LLC, which LLC is held by The Irrevocable Agreement of Trust of Alec Machiels (the "Trust"). The reporting person is the managing member of Bauhaus 1 LLC and the trustee of the Trust.
F3 Owned by spouse.
F4 On September 7, 2021, the reporting person's spouse transferred 150,000 shares of Apellis Pharmaceuticals, Inc. common stock to her trust, of which the reporting person is the trustee.
F5 This option was granted on December 5, 2013 and fully vested.